Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information ...

The drug is the second Alzheimer’s medicine to receive a lukewarm reception from the UK government in recent months.View on ...

Impairment in both an odor identification test and global cognition is comparable to positron emission tomography (PET) with 11C-Pittsburgh compound B (11C-PiB) for predicting cognitive decline and ...

Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...

There have been many promising leads for an Alzheimer's vaccine but new treatments have been slow to merge. Researchers at ...

A groundbreaking laser test can now detect dementia in just seconds, offering faster, cheaper, and more accurate diagnoses ...

Memory forensics enhances investigations by analysing volatile data (in RAM) unavailable in disk forensics. Key insights from ...

Nearly 7 million Americans 65 and older are living with Alzheimer’s disease, which gradually destroys memory and thinking ...

Donanemab has already been rejected in the NHS in England but Scottish Medicines Consortium has still to make a decision on ...

What is Donanemab and how does it work? Both Donanemab and Lecanemab are antibody drugs that binds to amyloid, a protein which builds up in the brains of those with Alzheimer’s disease. By binding to ...

Donanemab: Everything we know about the latest Alzheimer’s drug rejected by the NHS - Donanemab and another new drug for ...

How a new blood test could speed up Alzheimer’s diagnoses How a new blood test could speed up Alzheimer’s diagnoses Dementia has no cure. But there’s hope for better care. Dementia has no cure. But ...